Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

NSCLC, metastatic

1266 - Nivolumab in previously treated patients with metastatic squamous NSCLC: results of a European single-arm, phase 2 trial (CheckMate 171) including patients aged ≥70 years and with poor performance status

Date

10 Sep 2017

Session

NSCLC, metastatic

Presenters

Sanjay Popat

Citation

Annals of Oncology (2017) 28 (suppl_5): v460-v496. 10.1093/annonc/mdx380

Authors

S. Popat1, A. Ardizzoni2, T. Ciuleanu3, M. Cobo Dols4, K. Laktionov5, M. Szilasi6, R. Califano7, E. Carcereny Costa8, R. Griffiths9, L. Paz-Ares10, C. Szczylik11, J. Corral12, D. Isla13, J. Jassem14, W. Appel15, J. Van Meerbeeck16, J. Wolf17, J. Jiang18, L..R. Molife18, E. Felip Font19

Author affiliations

  • 1 Medical Oncology, Royal Marsden Hospital, SW3 6JJ - London/GB
  • 2 Medical Oncology, Policlinico Sant’Orsola – Malpighi, 40138 - Bologna/IT
  • 3 Medical Oncology, The Oncology Institute Prof. Dr. Ion Chiricuta, Cluj-Napoca/RO
  • 4 Medical Oncology, Hospital Regional Universitario de Malaga, Malaga/ES
  • 5 Medical Oncology, N.N. Blokhin Russian Cancer Research Center, Moscow/RU
  • 6 Medical Oncology, Debreceni Egyetem Klinikai Kozpont, Debrecen/HU
  • 7 Medical Oncology, The Christie NHS Foundation Trust, Manchester/GB
  • 8 Thoracic Tumors, Instituto Catalan de Oncologia (ICO Badalona), Barcelona/ES
  • 9 Medical Oncology, The Clatterbridge Cancer Centre, Bebington/GB
  • 10 Medical Oncology, Hospital Universitario 12 de Octubre, Madrid/ES
  • 11 Medical Oncology, Wojskowy Instytut Medyczny, Warsaw/PL
  • 12 Medical Oncology, Virgen del Rocio University Hospital, Seville/ES
  • 13 University Hospital Lozano Blesa, Medical Oncology, Zaragoza/ES
  • 14 Oncology And Radiotherapy, Medical University of Gdansk, Gdańsk/PL
  • 15 Medical Oncology, Lancashire Teaching Hospitals NHS Foundation Trust, Preston/GB
  • 16 Medical Oncology, Antwerp University Hospital, Edegem/BE
  • 17 Medical Oncology, Center for Integrated Oncology, University Hospital of Cologne, Cologne/DE
  • 18 Medical Oncology, Bristol-Myers Squibb, Princeton/US
  • 19 Thoracic Tumors, Vall D'Hebron University Hospital, Barcelona/ES
More

Resources

Abstract 1266

Background

Nivolumab, a fully human PD-1 immune checkpoint inhibitor antibody, demonstrated a favorable efficacy and safety profile in previously treated SQ NSCLC in a phase 3 trial (CheckMate 017), with significantly longer OS (median 9.2 mo) and fewer treatment-related (TR) grade 3–4 AEs (7%) vs. docetaxel (median OS: 6.0 mo; grade 3–4 TRAEs: 55%). In a North American community-based study (CheckMate 153; SQ/non-SQ NSCLC), nivolumab showed comparable efficacy and safety to that observed in controlled clinical trials.

Methods

Patients aged ≥18 yr from 13 European countries with advanced SQ NSCLC, progressive disease after ≥1 systemic treatment, and ECOG performance status (PS) 0–2 were eligible to receive nivolumab. The primary objective of the study (NCT02409368) was to evaluate safety. OS and ORR were secondary objectives.

Results

809 patients were enrolled: 79% male and 93% current/former smokers. Most patients had received 1 (42%) or 2 (40%) prior lines of therapy. Median duration of nivolumab therapy was 4.4 mo (range: 0.0, >14.7). 324 patients (40%) were continuing treatment at database lock. 403 patients (50%) had TRAEs. 95 (12%) had grade 3–4 TRAEs, most frequently asthenia (12 [2%]) and fatigue (10 [1%]). Of the 5 cases (1%) of TR grade 3–4 pneumonitis, 3 had a documented resolution, and in these patients, resolution occurred within 5 wk. TRAEs led to treatment discontinuation in 45 patients (6%), most commonly pneumonitis, asthenia, and fatigue (7, 5, and 5 patients each). 2 deaths were deemed TR. Median OS was 9.9 mo (95% CI: 8.7, 13.1). In the subgroup aged ≥70 yr (n = 279), 155 patients (56%) had TRAEs and 16 (6%) discontinued due to TRAEs. In the subgroup with ECOG PS 2 (n = 98), 45 patients (46%) had TRAEs and 5 (5%) discontinued due to TRAEs. Additional data including outcomes in the age ≥70 yr and ECOG PS 2 subgroups will be presented.

Conclusions

The safety of nivolumab in this study was consistent with prior studies of nivolumab in previously treated SQ NSCLC, with no new safety signals. Tolerability in patients aged ≥70 yr or with ECOG PS 2 was comparable to the overall population.

Clinical trial identification

NCT02409368

Legal entity responsible for the study

Bristol-Myers Squibb

Funding

Bristol-Myers Squibb and Ono

Disclosure

S. Popat: Honoraria from Merck, Pfizer; served as a consultant/advisor for BI, Eli Lilly, Novartis, Roche, Pfizer (Inst), BI (Inst), BMS (Inst), MSD (Inst); received institutional research funding from BI, Roche, BMS, Clovis; travel: BI, MSD, BMS. A. Ardizzoni: Honoraria from Eli Lilly, BMS, MSD, BI; served as a consultant/advisor for Eli Lilly, BMS, MSD, BI, GSK. T. Ciuleanu: Advisor for Amgen, Astellas, AZ, BI, BMS, Eli Lilly, Ipsen, Janssen, Merck, Novartis, Pfizer, Roche, Sandoz, Sanoi, Serono, Servier, Teva. R. Califano: Consultant/advisor for AstraZeneca, Roche, Clovis Oncology, Novartis, and Pfizer. R. Griffiths: Teaching honoraria from Bristol-Myers Squibb. W. Appel: Consultant or advisor for Amgen, AstraZeneca, and Boehringer Ingelheim; travel funding from Amgen. J. Wolf: Personal fees from University Hospital of Cologne; grants and personal fees from AZ, Novartis, Roche, Pfizer, BI, BMS, Clovis, and nonfinancial support from Novartis, Roche, BI, outside of the submitted work. J. Jiang, L.R. Molife: Employed by BMS and owns stock in BMS. E. Felip Font: Honoraria from BI, MSD, Eli Lilly, Roche, Pfizer, Novartis, BMS, Celgene; Consultant for BI, MSD, Eli Lilly, Roche, Pfizer, Novartis, BMS, Celgene; participated on speakers’ bureau for BMS, Novartis, and Roche. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings